Clinic HIV-focused features and prevention of Pneumocystis carinii pneumonia.
OBJECTIVE
To examine the association of clinic HIV-focused features and advanced HIV care experience with Pneumocystis carinii pneumonia (PCP) prophylaxis and development of PCP as the initial AIDS diagnosis.


METHODS
Nonconcurrent prospective study.


METHODS
New York State Medicaid Program.


METHODS
Medicaid enrollees diagnosed with AIDS in 1990-1992.


RESULTS
We collected patient clinical and health care data from Medicaid files, conducted telephone interviews of directors of 125 clinics serving as the usual source of care for study patients, and measured AIDS experience as the cumulative number of AIDS patients treated by the study clinics since 1986. Pneumocystis carinii pneumonia prophylaxis in the 6 months before AIDS diagnosis and PCP at AIDS diagnosis were the main outcome measures. Bivariate and multivariate analyses adjusted for clustering of patients within clinics. Of 1,876 HIV-infected persons, 44% had PCP prophylaxis and 38% had primary PCP. Persons on prophylaxis had 20% lower adjusted odds of developing PCP (95% confidence interval [CI] 0.64, 0.99). The adjusted odds of receiving prophylaxis rose monotonically with the number of HIV-focused features offered by the clinic, with threefold higher odds (95% CI 1.6, 5.7) for six versus two or fewer such features. Patients in clinics with three HIV-focused features had 36% lower adjusted odds of PCP than those in clinics with one or none. Neither clinic experience nor specialty had a significant association with prophylaxis or PCP.


CONCLUSIONS
PCP prevention in our study cohort appears to be more successful in clinics offering an array of HIV-focused features.
Turner
B J
BJ
Center for Research in Medical Education and Health Care, Department of Medicine, Jefferson Medical College, Philadelphia, Pa 19107-5083, USA.
Markson
L
L
Cocroft
J
J
Cosler
L
L
Hauck
W W
WW
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000517:prevention & control*; D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D005260:Female; D015497:HIV-1; D006801:Humans; D008297:Male; D008484:Medicaid; D008875:Middle Aged; D009518:New York; D016017:Odds Ratio; D010419:Pentamidine / Q000008:administration & dosage / Q000627:therapeutic use*; D011010:Pneumocystis; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000517:prevention & control*; D011446:Prospective Studies; D011795:Surveys and Questionnaires; D014481:United States
D000336:Aerosols; D000935:Antifungal Agents; D000998:Antiviral Agents; D010419:Pentamidine